Form 4: Jazz Pharma Director's Stock Activity

A Jazz Pharmaceuticals director acquired new restricted stock units and sold shares to cover tax obligations from a prior vesting.

Summary

• Heather Ann McSharry, a Director at Jazz Pharmaceuticals plc, reported changes in her beneficial ownership.
• On August 7, 2025, she acquired 3,507 ordinary shares in the form of restricted stock units (RSUs) under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• These RSUs represent a contingent right to receive one ordinary share per unit and are scheduled to vest in full on July 24, 2026, subject to continuous service.
• On August 8, 2025, she disposed of 1,959 ordinary shares at a price of $111.2497 per share.
• This disposition was specifically to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• Following these transactions, her direct beneficial ownership stands at 20,449 ordinary shares.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving a grant of restricted stock units and a subsequent sale to cover tax obligations. The RSU grant is a positive for the director, aligning interests, while the sell-to-cover is a neutral, common event. It does not indicate any significant positive or negative news for the company's operations or financial health.

Positives

• Director Heather Ann McSharry received a grant of 3,507 restricted stock units, aligning her interests with shareholders.

Negatives

• No specific negative information about the company's performance or outlook is contained in this routine insider transaction report.

Risks

• No specific risks related to the company's operations or financial health are detailed in this Form 4 filing.

Future Outlook

This filing, a routine insider transaction report, does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a standard disclosure of insider trading activity and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing is a routine insider transaction report and does not contain information that allows for a comparison of company results against global benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns management's interests with shareholders, while the sell-to-cover is a routine, non-material transaction.

Next Steps

• The 3,507 restricted stock units granted on August 7, 2025, are scheduled to vest in full on July 24, 2026.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Share Ownership